Prophylactics/Therapeutics for Neurotoxin Exposure
Closed Solicitation Posted
- Solicitation number
- CBD254-004
- Agency
-
Joint PEO Chemical and Biological Defense
Acquisition Support Center, Department of Defense
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- More information
Notice details come from DoD SBIR/STTR (DSIP). Updated .
About this opportunity
The Department of the Army Acquisition Support Center's Joint PEO Chemical and Biological Defense seeks Phase I SBIR proposals for prophylactic and therapeutic countermeasures against G-type and V-type nerve agent neurotoxins under DoD topic CBD254-004, under a Total Small Business set-aside. The February 26, 2025 proposal deadline has passed.
Proposals are submitted through the Defense SBIR/STTR Innovation Portal (DSIP). The attached proposal instructions (CBD_SBIR_254_R4.pdf) cover the CBD SBIR FY25.4 Release 4, which the Joint Science and Technology Office for Chemical and Biological Defense manages at the Defense Threat Reduction Agency. Phase I proposals are limited to 20 pages with awards up to $209,575 for up to six months of performance. Direct to Phase II proposals are limited to 15 pages, with awards of $698,582.50 for a 12-month base and a 12-month option, not to exceed $1,397,165.00 total. Phase I awardees may compete for Phase II, but Phase II submission cannot occur before five months after Phase I award.
Phase I requires assays measuring PTE and/or OPAA turnover rates on model compounds under thermal and chemical denaturing conditions, with a plan for access to multiple nerve agent classes. The objective is enzyme stabilization for circulation in blood for several months, delivered as human-compatible formulations for intramuscular or subcutaneous injection. Phase II requires milligram-quantity prototypes with documented deactivation efficacy against multiple nerve agent classes under physiological conditions, including turnover rates and lifetimes for each compound. Offerors must disclose foreign nationals, green card holders, and dual citizens involved on projects. Direct to Phase II applicants must also comply with human subjects and animal use requirements and verify intellectual property ownership.
Proposals are evaluated on three criteria per the DoD Program BAA, and the source assigns no weights. The program reserves the right to limit awards and withdraw from negotiations for national security reasons, and it may elect to fund multiple or no approaches to the same topic. No CMMC level requirement is imposed. The source names no incumbent contractor and no place of performance.
Notice text
DoD SBIR topic CBD254-004
Component: CBD
Command: CBD
Phase: SBIR Program Phase I Action
Technology Areas: Chem Bio Defense
Focus Areas: Biotechnology
Keywords: Neurotoxins; deactivation; enzyme; therapeutic; stabilization; toxicity; bioavailability
ITAR: No
Objective:
A biological agent is sought to prevent illness upon exposure to chemical warfare nerve agents, to include G-type or V- type neurotoxins, by either administering a prophylactic before anticipated exposure or administering a therapeutic after symptoms of exposure. Phase II will demonstrate robust deactivation of neurotoxins in vitro with foundational studies targeting appropriate efficacy and pharmacokinetics to include physiological half-life, clearance, and tolerance.
Description:
The primary problem this topic addresses are gaps in our ability to sustain troops on the battlefield under exposure to chemical weapons. Furthermore, chemical attacks on the homeland would place U.S. civilians in harm’s way without an effective remedy. Organophosphorus compounds pose significant threats to military personnel. At lethal doses these agents act irreversibly on the nervous system, resulting in uncontrolled convulsions followed by rapid death. Butyrlcholinesterase is human enzyme that stoichometrically binds these compounds and prevents them from reaching their physiological targets. However, when produced endogenously, these large enzymes are difficult to prophylactically deliver in sufficient doses to mitigate expected organophosphorus compound exposure. Human Paraoxonase has been demonstrated to detoxify organophosphorus compounds. Phosphotriesterases (PTEs) and Organophosphate Acid Anhydrolase (OPAA) are enzymes that neutralize G-type nerve agents both environmentally and in the human body. Mutant PTE has even been developed for detoxification of the highly toxic V-type agents. Biodistribution profiles and protease susceptibility characteristics have prevented these enzyme-classes from employment as prophylactic agents or as post-exposure therapeutics.
This topic solicits innovative chemistries and approaches to render such enzymes stable in circulating blood over for up to several months and at sufficient levels to mitigate exposure to operationally relevant quantities of organophosphorus compounds while also considering biodistribution, toxicity, and clearance. Prophylactic and therapeutic doses of protected OPAA and PTE would ideally be injected intramuscularly or subcutaneously to rapidly neutralize nerve agents in vivo and minimize acute and chronic injuries. A prophylactic and therapeutic chemical medical countermeasure comprised of human-compatible formulations containing neuro-protective enzymes would enable military and ultimately civilian use for protection against nerve agents in combat scenarios and therapeutic treatment in combat and non-combat scenarios.
Phase I:
Phase I will demonstrate ability to perform assays probing PTE and/or OPAA turnover rates for chemical reactions on model compounds that mimic deactivation of a multiple nerve agents. The studies will characterize catalyst performance under various destabilizing environments such as thermal and chemical denaturing conditions comparing wild-type enzyme and enzyme with some degree of stabilization chemistry employed. A target is demonstrating turnover rates for stabilized enzyme that approach wild-type values. Phase I will provide a plan for access to multiple classes of nerve agents and the ability to work with these samples which may involve exploiting or establishing an enabling collaboration with a partner having these abilities.
Phase II:
Phase II will deliver prototype MCMs wherein the enzyme has been demonstrated to retain catalytic activity after being stabilized against various denaturing conditions. The delivered compounds, produced in mg quantities, will be characterized for deactivation of multiple classes of nerve agents under chemical and biochemical conditions comparable to physiological exposure. Turnover rates and lifetimes will be rigorously documented for each compound for multiple nerve agents. Top candidate drugs/biological agents emerging from these systematic studies will be bolstered to increase performance in both activity and stability. Ultimately at the end of Phase II, mg quantities of the best performing compounds will be delivered for Phase III animal studies.
Phase III:
PHASE III: The goal of Phase III work will be to evaluate the protective formulations for the peripheral and central nervous systems though animal studies. Evaluating how the compounds distribute throughout the body, accumulate in specific tissues, and are cleared will enables the refinement of further design to enhance stability, prolong circulation time, and catalysts compounds remain active for longer durations. Ultimately, Phase III will pursue (1) intramuscular administration with (2) peripheral and central nervous system entry and (3) long duration of circulation and enzyme activity. Higher animal models beyond mice and towards enabling human clinical trials is a goal of Phase III.
PHASE III DUAL USE APPLICATIONS: The delivered therapeutic will allow medical intervention for the domestic public that would be needed after a domestic involving G-type nerve agents or during an organophosphorus insecticide accidental spill or exposure. The treatment would also be available for CONUS troops.
Files
| File | Type | Posted |
|---|---|---|
| CBD254-004.pdf | ||
| CBD_SBIR_254_R4.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity